The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HSDT | -99.16% | -100% | -89.55% | -100% |
| S&P | +13.22% | +85.17% | +13.11% | +245% |
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.
No news articles found for Solana.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.70M | 1266.7% |
| Gross Profit | $0.59M | 515.4% |
| Gross Margin | 85.22% | 365.6% |
| Market Cap | $16.04M | 683.8% |
| Market Cap / Employee | $0.76M | 0.0% |
| Employees | 21 | -4.5% |
| Net Income | -$352.77M | -9470.5% |
| EBITDA | -$4.91M | -21.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $124.05M | 3477.0% |
| Accounts Receivable | $0.01M | -90.1% |
| Inventory | 1.1 | 45.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -153.84% | -31.1% |
| Return On Invested Capital | -435.61% | -190.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.04M | -45.9% |
| Operating Free Cash Flow | -$4.04M | -45.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.36 | 1.92 | 1.03 | 1.68 | 212.12% |
| Price to Sales | 4.81 | 6.98 | 3.80 | 169.69 | 3957.24% |
| Price to Tangible Book Value | 482.75 | 1058.78 | 0.06 | 1.68 | -99.21% |
| Enterprise Value to EBITDA | -0.46 | -0.48 | 1.50 | -7.26 | -2286.65% |
| Return on Equity | -259.8% | -688.9% | -800.0% | -344.3% | 112.56% |
| Total Debt | $0.01M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
